Management experience of advanced-stage mycosis fungoides/ Sézary syndrome: a retrospective study from Spanish haematology referral units.

Background Advanced-stage mycosis fungoides/Sezary syndrome (aMF/SS) has a dismal outcome. The only curative treatment is allogeneic stem cell transplantation (allo-SCT) but this is limited to selected candidates, thus palliative therapy is the most frequent strategy. Objectives To describe the characteristics of aMF/SS in cases referred to haematology units for advanced/palliative therapy. Materials and methods Data from 30 patients were collected from four centres, and descriptive statistics, frequencies and survival analyses were calculated. Results Eighty-eight per cent of patients received systemic therapy. The median number of therapies was three (range: 1-9). Bexarotene (21%), CHOP-like chemotherapy (10%) and methotrexate (9%) were the more common treatments. The overall survival at a median follow-up of 28 months (range: 8-65 months) for aMF/SS was 56.9%. Survival probability was more favourable for MF (p Conclusion There is significant heterogeneity in aMF/SS treatments. Survival is more favourable for MF compared to SS. Current chemoimmunotherapies are insufficient to control disease, making allo-SCT the best therapeutic approach in selected patients.